Literature DB >> 15912714

Depression therapy with injection drug users: results of a pilot study.

Wesley E Hawkins1, Carl Latkin, Diane L Green.   

Abstract

The purpose of this article is to report the methods, results, and conclusions of a pilot study developed to test a depression therapy component to reduce depressive symptoms in injection drug users. The pilot study was conducted to determine if the depression therapy component should be added as an adjunct to a social-network HIV risk-reduction intervention. The major conclusion from our pilot study was that depression therapy appears to be effective in reducing depressive symptoms in injection drug users and should be tested to improve treatment outcome of depressed drug users participating in HIV risk-reduction interventions.

Entities:  

Mesh:

Year:  2005        PMID: 15912714

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  4 in total

1.  Gender, HIV status, and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Mariana Lopes; Mark Olfson; Judith Rabkin; Deborah S Hasin; Analucía A Alegría; Keng-Han Lin; Bridget F Grant; Carlos Blanco
Journal:  J Clin Psychiatry       Date:  2011-10-18       Impact factor: 4.384

2.  Social network members' roles and use of mental health services among drug users in New York City.

Authors:  Katherine J Sapra; Natalie D Crawford; Abby E Rudolph; Kandice C Jones; Ebele O Benjamin; Crystal M Fuller
Journal:  J Behav Health Serv Res       Date:  2013-10       Impact factor: 1.505

3.  The impact of an integrated treatment on HIV risk behavior among homeless youth: a randomized controlled trial.

Authors:  Natasha Slesnick; Min Ju Kang
Journal:  J Behav Med       Date:  2007-10-17

4.  RCT of an integrated CBT-HIV intervention on depressive symptoms and HIV risk.

Authors:  Karin Tobin; Melissa A Davey-Rothwell; Bareng A S Nonyane; Amy Knowlton; Lawrence Wissow; Carl A Latkin
Journal:  PLoS One       Date:  2017-12-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.